Archives of neurology
-
Archives of neurology · Oct 2011
Clinical TrialRisk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
To perform a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial, which tested the effect of treatment with atorvastatin in reducing stroke in subjects with a recent stroke or transient ischemic attack, to explore the effects of treatment in subjects with type 2 diabetes mellitus or metabolic syndrome (MetS). ⋯ The SPARCL subjects with type 2 diabetes were at higher risk for recurrent stroke and cardiovascular events. This exploratory analysis found no difference in the effect of statin treatment in reducing these events in subjects with or without type 2 diabetes or MetS. Trial Registration clinicaltrials.gov Identifier: NCT00147602.
-
Archives of neurology · Oct 2011
Case ReportsStatus epilepticus-induced hyperemia and brain tissue hypoxia after cardiac arrest.
To report changes of cerebral blood flow and metabolism associated with status epilepticus after cardiac arrest. ⋯ Brain multimodality monitoring is a feasible method for evaluating secondary brain injury associated with seizure activity after cardiac arrest.
-
Archives of neurology · Oct 2011
Letter Case Reports Biography Historical ArticleEvidence and the effective clinical neurologist: the 2009 H. Houston Merritt lecture.
-
Archives of neurology · Sep 2011
Biography Historical ArticleIn memoriam: John W. “Jack” Griffin, MD.
-
Archives of neurology · Sep 2011
Comparative StudyComparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology.
Cerebrospinal fluid (CSF) biomarkers of Alzheimer disease (AD) are currently being considered for inclusion in revised diagnostic criteria for research and/or clinical purposes to increase the certainty of antemortem diagnosis. ⋯ The INNOTEST and INNO-BIA CSF platforms perform equally well in identifying individuals with underlying amyloid plaque pathology. Differences in absolute values, however, point to the need for assay-specific diagnostic cutoff values.